Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology

Core Insights - Milestone Pharmaceuticals Inc. is set to present findings on etripamil's effectiveness in treating Paroxysmal Supraventricular Tachycardia (PSVT) at the American College of Cardiology annual meeting [1][2] - The data suggests that etripamil can convert multiple PSVT episodes to restore normal sinus rhythm, potentially enhancing patient quality of life [2][3] Company Overview - Milestone Pharmaceuticals focuses on developing innovative cardiovascular solutions aimed at improving the lives of patients with complex heart conditions [3] - The company's lead product, etripamil, is a novel calcium channel blocker nasal spray designed for self-administration by patients experiencing symptomatic episodic attacks associated with PSVT and AFib-RVR [3] Presentation Details - The moderated poster presentation titled "Consistency and Predictiveness of Conversion Among Multiple Episodes of Paroxysmal Supraventricular Tachycardia (PSVT) Treated with Etripamil: Outcomes from the NODE-303 trial" will be presented by Dr. James Ip [2] - The presentation is scheduled for March 30, 2025, from 11:42 to 11:49 AM Central Time at the ACC25 event in Chicago [2]